Tech Company Financing Transactions
Celsius Therapeutics Funding Round
Celsius Therapeutics, operating out of Cambridge, secured $65 million from Third Rock Ventures, Alexandria Venture Investments and Casdin Capital.
Transaction Overview
Company Name
Announced On
5/16/2018
Transaction Type
Venture Equity
Amount
$65,000,000
Round
Series A
Investors
Third Rock Ventures (Lead Investor) (Christoph Lengauer)
Proceeds Purpose
With the new level of clarity provided by single-cell sequencing, our team will be able to address many of the challenges of the current treatments and introduce a new class of medicines that will lead to better outcomes and potential cures.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
399 Binney St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Celsius Therapeutics is charting a new course of target and drug discovery by understanding the specific cells, among many others, that are key players in disease and by identifying the genes that are triggering their malfunction.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Alexis Borisy
Chief Executive Officer
Tariq Kassum
Chief Scientific Officer
Christoph Lengauer
VP - Bus. Development
Michael Boretti
VP - Human Resources
Andrea Armstrong
Browse more venture capital transactions:
Prev: 5/16/2018: Motorleaf venture capital transaction
Next: 5/16/2018: Vesper venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to document all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs